Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

871
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
871

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Androgen Receptor Variant 7 (AR-V7) Transcript Expression in Circulating Tumor Cells.

Methods in molecular biology (Clifton, N.J.)·2026
Same author

Androgen Receptor Variant 7 (AR-V7) Protein Detection in Circulating Tumor Cells by Immunocytostaining.

Methods in molecular biology (Clifton, N.J.)·2026
Same author

Healthcare professionals' perspectives on the barriers and enablers of cancer clinical trial participation among Arabic-speaking cancer patients in Australia: a qualitative study.

Trials·2026
Same author

Novel treatments for novel side effects: a case report and review of baricitinib use in the treatment of chronic inflammatory demyelinating polyneuropathy caused by immune checkpoint inhibitor use.

Journal for immunotherapy of cancer·2026
Same author

Real-World Treatment and Outcomes in Resectable Early-Stage Non-Small Cell Cancer: THASSOS-INTL Australia Cohort.

Aging medicine (Milton (N.S.W))·2026
Same author

From Spatial Heterogeneity to Real-Time Monitoring: Liquid Biopsy for Genomic Profiling and MRD Assessment in Multiple Myeloma.

Cancers·2026

Related Experiment Video

Updated: Nov 21, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.3K

The Multiple Potential Biomarkers for Predicting Immunotherapy Response-Finding the Needle in the Haystack.

Tamiem Adam1,2,3, Therese M Becker1,4, Wei Chua1,2,3

  • 1Ingham Institute for Applied Medical Research, 1 Campbell St, Liverpool, NSW 2170, Australia.

Cancers
|January 16, 2021
PubMed
Summary

Predictive biomarkers are crucial for identifying patients who will benefit from immune checkpoint inhibitors (ICIs) and avoid immune-related adverse events (irAEs). Research is exploring tumor, blood, and microbiome markers to personalize cancer treatment.

Keywords:
NSCLCbiomarkerimmunotherapymelanomapredictiverenal cancerurothelial cancer

More Related Videos

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors
06:32

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors

Published on: August 18, 2023

2.6K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.1K

Related Experiment Videos

Last Updated: Nov 21, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.3K
Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors
06:32

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors

Published on: August 18, 2023

2.6K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.1K

Area of Science:

  • Oncology
  • Immunology
  • Biomarker Discovery

Background:

  • Immune checkpoint inhibitors (ICIs) show promise in advanced cancers but benefit only a subset of patients.
  • Many patients treated with ICIs experience severe immune-related adverse events (irAEs).
  • Predictive biomarkers are essential for treatment personalization and improving patient outcomes.

Purpose of the Study:

  • To review and highlight the potential of various biomarkers in predicting response to ICIs.
  • To emphasize the need for personalized medicine in advanced malignancies treated with ICIs.

Main Methods:

  • Review of existing literature on predictive biomarkers for ICI therapy.
  • Categorization of biomarkers based on their origin: tumor, blood, or microbiome.
  • Identification of specific biomarkers within each category, including PD-L1, TMB, STING, ASC, PBMCs, ctDNA, exosomes, cytokines, and microbiome composition.

Main Results:

  • Tumor-based biomarkers like PD-L1, TMB, STING, and ASC show promise.
  • Blood-based biomarkers including PBMCs, ctDNA, exosomes, and cytokines are under investigation.
  • The microbiome is emerging as a significant factor influencing ICI efficacy.

Conclusions:

  • A multi-faceted approach utilizing diverse biomarkers is necessary for effective ICI treatment personalization.
  • Further research into these predictive biomarkers will optimize patient selection and mitigate irAEs.
  • Personalized cancer therapy through biomarker development is key to improving outcomes in advanced malignancies.